Abstract:All-trans-retinoic acid (ATRA), the biologically most active metabolite of vitamin A, plays a major role in the regulation of cellular differentiation and proliferation, and it is also an important pharmacological agent particularly used in the treatment of cancer, skin, neurodegenerative and autoimmune diseases. However, ATRA is very easy to be metabolized into 4-hydroxyl-RA in vivo by CYP26A1, an inducible cytochrome P450 enzyme, eventually into more polar metabolites. Therefore, it is vital to develop specific retinoic acid metabolism blocking agents (RAMBAs) to inhibit the metabolic enzyme CYP26A1 in the treatment of relevant diseases aforementioned.In this study, CYP26A1 and its interactions with retinoic acid-competitive metabolism blocking agents were investigated by a combined ligand- and structure-based approach. First, since the crystal structure of CYP26A1 protein has not been determined, we constructed the 3D structure of CYP26A1 using homology modeling. In order to achieve a deeper insight into the mode of action of RAMBAs in the active site, the molecular superimposition model and the common feature pharmacophore model were constructed, and molecular docking was performed. The molecular superimposition model is composed of three features: the main chain groups, side chain groups, and azole groups. The common feature pharmacophore model consists of five chemical features: four hydrophobic groups and one hydrogen acceptor (HHHHA). The results of molecular docking show that the characteristic groups of RAMBAs were mapped into three different active pockets, respectively.A structure-activity relationship (SAR) was obtained by a combination of the molecular superimposition and docking results with the pharmacophore model. This study gives more insight into the interaction model inside the CYP26A1 active site and provides guidance for the design of more potent and possibly more selective RAMBAs. (C) 2014 Elsevier Inc. All rights reserved.

Structural Development of Silicon-Containing Retinoids: Structure-Activity Relationship Study of the Hydrophobic Pharmacophore of Retinobenzoic Acids Using Silyl Functionalities

Molecular Recognition of CYP26A1 Binding Pockets and Structure–activity Relationship Studies for Design of Potent and Selective Retinoic Acid Metabolism Blocking Agents

Design, Synthesis, And Sar Studies Of Heteroarylpyrimidines And Heteroaryltriazines As Cb2r Ligands

THE SYNTHESIS AND PRELIMINARY EVALUATION OF SUBSTITUTED CHROMONES, COUMARINS, CHROMANONES, AND BENZOPHENONES AS RETINOIC ACID RECEPTOR LIGANDS

Structural Basis for Retinoic X Receptor Repression on the Tetramer

Identification of A Chromone-Based Retinoid Containing A Polyolefinic Side Chain Via Facile Synthetic Routes

Structure-guided design of a highly potent RXR agonist with superior physicochemical properties

Structure-Guided Design of a Highly Potent Partial RXR Agonist with Superior Physicochemical Properties

Discovery of Novel N -Sulfonamide-tetrahydroquinolines as Potent Retinoic Acid Receptor-Related Orphan Receptor γt (RORγt) Inverse Agonists for the Treatment of Psoriasis

Discovery and Structural Optimization of 4-(4-(benzyloxy)phenyl)-3,4-dihydropyrimidin-2(1h)-ones As RORc Inverse Agonists

Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Synthesis and in vitro biological activity of retinyl retinoate, a novel hybrid retinoid derivative

Discovery and mechanistic study of thiazole-4-acylsulfonamide derivatives as potent and orally active ChemR23 inhibitors with a long-acting effect in cynomolgus monkeys

Discovery of novel RARα agonists using pharmacophore-based virtual screening, molecular docking, and molecular dynamics simulation studies

Design, Synthesis and Evaluation of Indene Derivatives As Retinoic Acid Receptor Α Agonists

Identification of N-phenyl-2-(N-phenylphenylsulfonamido)acetamides as new RORγ inverse agonists: Virtual screening, structure-based optimization, and biological evaluation.

Structural basis for the full and partial agonist activities of retinoid X receptor α ligands with an iso-butoxy and an isopropyl group

Semi-synthesis and Structure-Activity Relationship of Neuritogenic Oleanene Derivatives.

Derivation of a Retinoid X Receptor Scaffold from Peroxisome Proliferator‐Activated Receptor Γ Ligand 1‐Di(1h‐indol‐3‐yl)methyl‐4‐trifluoromethylbenzene

Synthesis and biological evaluation of new C-10 substituted dithranol pleiotropic hybrids

3D-QSAR, molecular docking and molecular dynamics studies of a series of RORγt inhibitors.